Clinical Trial Update: 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the Hsp90 inhibitor tanespimycin (17-AAG) in patients with advanced epithelial cancers, malignant lymphomas, or sarcomas; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Burkitt Lymphoma
• Chondrosarcoma
• Ewing Sarcoma
• Hodgkin Lymphoma
• Non-hodgkin Lymphoma
• Osteosarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• tanespimycin (17-N-allylamino-17-demethoxygeldanamycin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma | Phase 1 | Status: COMPLETED